Therapy  	Therapy  	 NN	O
with  	with  	 IN	O
high-doses  	high-doses  	 JJ	B-NP
of  	of  	 IN	O
antithrombin  	antithrombin  	 JJ	O
III  	III  	 NNP	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
septic  	septic  	 JJ	B-NP
shock  	shock  	 NN	I-NP
and  	and  	 CC	O
agranulocytosis  	agranulocytosis  	 VBG	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
assess  	assess  	 VB	O
efficacy  	efficacy  	 VBN	O
of  	of  	 IN	O
high-doses  	high-doses  	 JJ	B-NP
ofantithrombin  	ofantithrombin  	 NN	I-NP
111  	111  	 CD	O
( 	( 	 -LRB-	O
AT 	AT 	 NNP	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
septic  	septic  	 JJ	B-NP
shock  	shock  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
an  	an  	 DT	O
agranulocytosis 	agranulocytosis 	 NN	B-NP
.  	.  	 .	O
Prospective 	Prospective 	 JJ	O
,  	,  	 ,	O
controlled  	controlled  	 VBD	B-NP
study.  	study.  	 CD	I-NP
29  	29  	 CD	O
patients  	patients  	 NNS	O
from  	from  	 IN	O
18  	18  	 CD	O
to  	to  	 TO	O
74  	74  	 CD	O
years  	years  	 NNS	O
old 	old 	 JJ	O
,  	,  	 ,	O
with  	with  	 IN	O
blood  	blood  	 NN	O
diseases  	diseases  	 NNS	O
complicated  	complicated  	 VBN	O
with  	with  	 IN	O
septic  	septic  	 JJ	B-NP
shock  	shock  	 NN	I-NP
Dates  	Dates  	 NNS	I-NP
of  	of  	 IN	O
study 	study 	 NN	O
:  	:  	 :	O
from  	from  	 IN	O
2006  	2006  	 CD	O
to  	to  	 TO	O
2012 	2012 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
randomized  	randomized  	 VBN	O
into  	into  	 IN	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
.  	.  	 .	O
Group-1  	Group-1  	 NNP	B-NP
included  	included  	 VBD	O
14  	14  	 CD	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
who  	who  	 WP	O
did  	did  	 VBD	O
not  	not  	 RB	O
receive  	receive  	 VB	O
AT  	AT  	 NNP	O
and  	and  	 CC	O
group-2  	group-2  	 NNP	B-NP
included  	included  	 VBD	O
15  	15  	 CD	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
received  	received  	 VBD	O
AT 	AT 	 NNP	O
.  	.  	 .	O
Demographic  	Demographic  	 JJ	B-NP
indicators 	indicators 	 NNS	I-NP
,  	,  	 ,	O
condition  	condition  	 NN	B-NP
severity  	severity  	 NN	I-NP
according  	according  	 VBG	O
to  	to  	 TO	O
APACHE  	APACHE  	 NNP	O
II 	II 	 NNP	O
,  	,  	 ,	O
level  	level  	 NN	O
of  	of  	 IN	O
thrombocytopenia 	thrombocytopenia 	 NN	B-NP
,  	,  	 ,	O
levels  	levels  	 NNS	O
ofplasma  	ofplasma  	 JJ	B-NP
procalcitonin 	procalcitonin 	 NN	I-NP
,  	,  	 ,	O
interleukin-6  	interleukin-6  	 NNP	B-NP
( 	( 	 -LRB-	O
IL-6 	IL-6 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
C-reactive  	C-reactive  	 JJ	B-NP
protein  	protein  	 NN	I-NP
( 	( 	 -LRB-	O
CRP 	CRP 	 NNP	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
the  	the  	 DT	O
same  	same  	 JJ	O
in  	in  	 IN	O
both  	both  	 DT	O
groups 	groups 	 NNS	O
.  	.  	 .	O
Level  	Level  	 NN	O
of  	of  	 IN	O
AT  	AT  	 NNP	O
was  	was  	 VBD	O
decreased  	decreased  	 VBN	O
in  	in  	 IN	O
both  	both  	 DT	O
groups 	groups 	 NNS	O
;  	;  	 :	O
however  	however  	 RB	O
it  	it  	 PRP	O
was  	was  	 VBD	O
higher  	higher  	 JJR	O
in  	in  	 IN	O
the  	the  	 DT	O
group-1  	group-1  	 NNP	B-NP
( 	( 	 -LRB-	O
50 	50 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
60 	60 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
group-1 	group-1 	 NNP	B-NP
,  	,  	 ,	O
microorganisms  	microorganisms  	 NN	B-NP
were  	were  	 VBD	O
found  	found  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
blood  	blood  	 NN	O
of  	of  	 IN	O
9  	9  	 CD	O
patients 	patients 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
group-2 	group-2 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
microorganisms  	microorganisms  	 NN	B-NP
were  	were  	 VBD	O
found  	found  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
blood  	blood  	 NN	O
of  	of  	 IN	O
11  	11  	 CD	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Inflammation  	Inflammation  	 JJ	B-NP
markers  	markers  	 NN	I-NP
were  	were  	 VBD	O
decreased  	decreased  	 VBN	O
after  	after  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
septic  	septic  	 JJ	B-NP
shock  	shock  	 NN	I-NP
in  	in  	 IN	O
both  	both  	 DT	O
groups  	groups  	 NNS	O
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
decreasing  	decreasing  	 NN	O
of  	of  	 IN	O
procalcitonin  	procalcitonin  	 NN	B-NP
in  	in  	 IN	O
group-1  	group-1  	 NNP	B-NP
was  	was  	 VBD	O
from  	from  	 IN	O
43.8  	43.8  	 CD	O
to  	to  	 TO	O
1  	1  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml  	ml  	 NN	I-NP
in  	in  	 IN	O
14  	14  	 CD	O
days  	days  	 NNS	O
and  	and  	 CC	O
from  	from  	 IN	O
12.8  	12.8  	 CD	O
to  	to  	 TO	O
1.6  	1.6  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml  	ml  	 NN	I-NP
in  	in  	 IN	O
7  	7  	 CD	O
days  	days  	 NNS	O
in  	in  	 IN	O
group-2 	group-2 	 CD	B-NP
.  	.  	 .	O
The  	The  	 DT	O
decreasing  	decreasing  	 NN	O
of  	of  	 IN	O
CRP  	CRP  	 NNP	B-NP
in  	in  	 IN	O
group-1  	group-1  	 NNP	B-NP
was  	was  	 VBD	O
from  	from  	 IN	O
224  	224  	 CD	O
to  	to  	 TO	O
114  	114  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
l  	l  	 NN	I-NP
in  	in  	 IN	O
7  	7  	 CD	O
days  	days  	 NNS	O
and  	and  	 CC	O
from  	from  	 IN	O
146  	146  	 CD	O
to  	to  	 TO	O
60  	60  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
l  	l  	 NN	I-NP
in  	in  	 IN	O
14  	14  	 CD	O
days  	days  	 NNS	O
in  	in  	 IN	O
group-2 	group-2 	 CD	B-NP
.  	.  	 .	O
The  	The  	 DT	O
decreasing  	decreasing  	 NN	O
of  	of  	 IN	O
IL-6  	IL-6  	 CD	B-NP
in  	in  	 IN	O
group-1  	group-1  	 NNP	B-NP
was  	was  	 VBD	O
from  	from  	 IN	O
1617  	1617  	 CD	O
to  	to  	 TO	O
100  	100  	 CD	O
pg 	pg 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml  	ml  	 NN	I-NP
in  	in  	 IN	O
3  	3  	 CD	O
days  	days  	 NNS	O
and  	and  	 CC	O
from  	from  	 IN	O
5895  	5895  	 CD	O
to  	to  	 TO	O
77  	77  	 CD	O
pg 	pg 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml  	ml  	 NN	I-NP
in  	in  	 IN	O
7  	7  	 CD	O
days  	days  	 NNS	O
in  	in  	 IN	O
group-2 	group-2 	 CD	B-NP
.  	.  	 .	O
A  	A  	 DT	O
level  	level  	 NN	O
of  	of  	 IN	O
AT  	AT  	 NNP	O
was  	was  	 VBD	O
increased  	increased  	 VBN	O
only  	only  	 RB	O
in  	in  	 IN	O
group-2  	group-2  	 NNP	B-NP
( 	( 	 -LRB-	O
under  	under  	 IN	O
12 	12 	 CD	O
%  	%  	 NN	O
per  	per  	 IN	O
day 	day 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
28-day  	28-day  	 CD	O
survival  	survival  	 NN	O
was  	was  	 VBD	O
higher  	higher  	 JJR	O
in  	in  	 IN	O
group-2  	group-2  	 NNP	B-NP
( 	( 	 -LRB-	O
60  	60  	 CD	O
+ 	+ 	 CD	O
/ 	/ 	 CD	O
-  	-  	 :	O
13 	13 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
45  	45  	 CD	O
+ 	+ 	 CD	O
/ 	/ 	 CD	O
-  	-  	 :	O
13 	13 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
We  	We  	 PRP	O
did  	did  	 VBD	O
not  	not  	 RB	O
find  	find  	 VB	O
any  	any  	 DT	O
complications  	complications  	 NNS	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
AT  	AT  	 NNP	O
concentrate 	concentrate 	 NN	O
.  	.  	 .	O
Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
septic  	septic  	 JJ	B-NP
shock  	shock  	 NN	I-NP
with  	with  	 IN	O
high-doses  	high-doses  	 JJ	B-NP
of  	of  	 IN	O
antithrombin  	antithrombin  	 JJ	O
III  	III  	 NNP	O
was  	was  	 VBD	O
effective  	effective  	 JJ	O
and  	and  	 CC	O
safe  	safe  	 JJ	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
an  	an  	 DT	O
agranulocytosis 	agranulocytosis 	 NN	B-NP
.  	.  	 .	O
